Plunkett Research Online: Syndax Pharmaceuticals

SYNDAX PHARMACEUTICALS (SNDX:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company’s product candidate are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, .....



Syndax Pharmaceuticals
Ticker: SNDX
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 1 781 419-1400
Fax: 1 781 419-1420
Address: 35 Gatehouse Drive
Building D, Floor 3
Waltham, MA 02451 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing
ContactsDescription
Richard SheaCFO/Chief Accounting Officer/Treasurer
Michael MeyersChief Medical Officer/Senior VP
See More
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company’s product candidate are entinostat which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, .....See More See More

Auditor: Deloitte & Touche LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420132012
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: